Elodie Odore

OTX015 (MK‐8628), a novel BET inhibitor, displays <i>in vitro</i> and <i>in vivo</i> antitumor effects alone and in combination with conventional therapies in glioblastoma models

Caroline Berenguer‐Daizé, Lucile Astorgues‐Xerri, Elodie Odore et al. · International Journal of Cancer · 2016 · 147 citations · Full text

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

Elodie Odore, François Lokiec, Esteban Cvitkovic et al. · Clinical Pharmacokinetics · 2015 · 92 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +9

The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Ramiro Vázquez, María E. Riveiro, Lucile Astorgues‐Xerri et al. · Oncotarget · 2016 · 92 citations · Full text

Breast Oncology, Chemoprevention Strategy, Immunology +17

OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations

María E. Riveiro, Lucile Astorgues‐Xerri, Ramiro Vázquez et al. · Oncotarget · 2016 · 58 citations · Full text

Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

Patrice Herait, Céline Berthon, Catherine Thiéblemont et al. · Cancer Research · 2014 · 31 citations

Mixed-phenotype Acute Leukemia, Immunology, Tumor Biology +21